Full Text:   <2699>

CLC number: R73

On-line Access: 

Received: 2008-04-09

Revision Accepted: 2008-06-21

Crosschecked: 0000-00-00

Cited: 4

Clicked: 6647

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2008 Vol.9 No.8 P.602-609

http://doi.org/10.1631/jzus.B0820120


A fusion protein containing murine vascular endothelial growth factor and tissue factor induces thrombogenesis and suppression of tumor growth in a colon carcinoma model


Author(s):  Feng-ying HUANG, Yue-nan LI, Hua WANG, Yong-hao HUANG, Ying-ying LIN, Guang-hong TAN

Affiliation(s):  Hainan Provincial Key Laboratory of Tropical Medicine, Hainan Medical College, Haikou 571101, China

Corresponding email(s):   tanhoho@163.com

Key Words:  Thrombogenesis, Vascular endothelial growth factor (VEGF), Tissue factor (TF), Recombinant fusion protein


Feng-ying HUANG, Yue-nan LI, Hua WANG, Yong-hao HUANG, Ying-ying LIN, Guang-hong TAN. A fusion protein containing murine vascular endothelial growth factor and tissue factor induces thrombogenesis and suppression of tumor growth in a colon carcinoma model[J]. Journal of Zhejiang University Science B, 2008, 9(8): 602-609.

@article{title="A fusion protein containing murine vascular endothelial growth factor and tissue factor induces thrombogenesis and suppression of tumor growth in a colon carcinoma model",
author="Feng-ying HUANG, Yue-nan LI, Hua WANG, Yong-hao HUANG, Ying-ying LIN, Guang-hong TAN",
journal="Journal of Zhejiang University Science B",
volume="9",
number="8",
pages="602-609",
year="2008",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B0820120"
}

%0 Journal Article
%T A fusion protein containing murine vascular endothelial growth factor and tissue factor induces thrombogenesis and suppression of tumor growth in a colon carcinoma model
%A Feng-ying HUANG
%A Yue-nan LI
%A Hua WANG
%A Yong-hao HUANG
%A Ying-ying LIN
%A Guang-hong TAN
%J Journal of Zhejiang University SCIENCE B
%V 9
%N 8
%P 602-609
%@ 1673-1581
%D 2008
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B0820120

TY - JOUR
T1 - A fusion protein containing murine vascular endothelial growth factor and tissue factor induces thrombogenesis and suppression of tumor growth in a colon carcinoma model
A1 - Feng-ying HUANG
A1 - Yue-nan LI
A1 - Hua WANG
A1 - Yong-hao HUANG
A1 - Ying-ying LIN
A1 - Guang-hong TAN
J0 - Journal of Zhejiang University Science B
VL - 9
IS - 8
SP - 602
EP - 609
%@ 1673-1581
Y1 - 2008
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B0820120


Abstract: 
Induction of tumor vasculature occlusion by targeting a thrombogen to newly formed blood vessels in tumor tissues represents an intriguing approach to the eradication of primary solid tumors. In the current study, we construct and express a fusion protein containing vascular endothelial growth factor (VEGF) and tissue factor (TF) to explore whether this fusion protein has the capability of inhibiting tumor growth in a colon carcinoma model. The murine cDNA of VEGF A and TF were amplified by reverse transcriptase polymerase chain reaction (RT-PCR), and then cloned into prokaryotic expression plasmid pQE30 with a linker. The expression product recombinant VEGF-TF (rVEGF-TF) was purified and proved to have comparable enzyme activity to a commercial TF and the capability of specific binding to tumor vessels. Significant decrease of tumor growth was found in the mice administered with rVEGF-TF on Day 6 after initiated rVEGF-TF treatment (P<0.05), and the tumor masses in 2 of 10 mice were almost disappeared on Day 14 after the first treatment. In addition, valid thrombogenesis and tumor necrosis were observed in the tumor tissues injected with rVEGF-TF. Our results demonstrate that occlusion of tumor vasculature with rVEGF-TF is potentially an effective approach for cancer therapy.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1] Boehm, T., Folkman, J., Browder, T., O′Reilly, M.S., 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390(6658):404-407.

[2] Brown, L.F., Berse, B., Jackman, R.W., Tognazzi, K., Manseau, E.J., Dvorak, H.F., Senger, D.R., 1993. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol., 143(5):1255-1262.

[3] Davie, E.W., Fujikawa, K., Kisiel, W., 1991. The coagulation cascade: initiation, maintenance, and regulation. Bio-chemistry, 30(43):10363-10370.

[4] Denekamp, J., 1993. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br. J. Radiol., 66(783):181-196.

[5] Dvorak, H.F., Nagy, J.A., Dvorak, A.M., 1991. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells, 3(3):77-85.

[6] Ferrara, N., 2004. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev., 25(4):581-611.

[7] Folkman, J., 1990. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82(1):4-6.

[8] Folkman, J., 1992. The role of angiogenesis in tumor growth. Semin Cancer Biol., 3(2):65-71.

[9] Gille, H., Kowalski, J., Li, B., LeCouter, J., Moffat, B., Zioncheck, T.F., Pelletier, N., Ferrara, N., 2001. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). J. Biol. Chem., 276(5):3222-3230.

[10] Hu, P., Yan, J., Sharifi, J., Bai, T., Khawli, L.A., Epstein, A.L., 2003. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res., 63(16):5046-5053.

[11] Huang, X., Molema, G., King, S., Watkins, L., Edgington, T.S., Thorpe, P.E., 1997. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science, 275(5299):547-550.

[12] Huang, X., Ding, W.Q., Vaught, J.L., Wolf, R.F., Morrissey, J.H., Harrison, R.G., Lind, S.E., 2006. A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties. Blood, 107(3):980-986.

[13] Jain, R.K., 1994. Barriers to drug delivery in solid tumors. Sci. Am., 271(1):58-65.

[14] Jiao, J.G., Li, Y.N., Wang, H., Liu, Q., Cao, J.X., Bai, R.Z., Huang, F.Y., 2006. A plasmid DNA vaccine encoding the extracellular domain of porcine endoglin induces anti-tumour immune response against self-endoglin-related angiogenesis in two liver cancer models. Dig. Liver Dis., 38(8):578-587.

[15] Kerbel, R.S., 1991. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays, 13(1):31-36.

[16] Matsuno, F., Haruta, Y., Kondo, M., Tsai, H., Barcos, M., Seon, B.K., 1999. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin. Cancer Res., 5(2):371-382.

[17] Millauer, B., Wizigmann-Voos, S., Schnurch, H., Martinez, R., Moller, N.P., Risau, W., Ullrich, A., 1993. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell, 72(6):835-846.

[18] Paleolog, E.M., 1996. Angiogenesis: a critical process in the pathogenesis of RA-a role for VEGF? Rheumatology, 35(10):917-919.

[19] Risau, W., 1997. Mechanisms of angiogenesis. Nature, 386(6626):671-674.

[20] Robinson, C.J., Stringer, S.E., 2001. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci., 114(5):853-865.

[21] Ruf, W., Rehemtulla, A., Morrissey, J.H., Edgington, T.S., 1991. Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J. Biol. Chem., 266(4):2158-2166.

[22] Shinkai, A., Ito, M., Anazawa, H., Yamaguchi, S., Shitara, K., Shibuya, M., 1998. Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J. Biol. Chem., 273(47):31283-31288.

[23] Tan, G.H., Wei, Y.Q., Tian, L., Zhao, X., Yang, L., Li, J., He, Q.M., Wu, Y., Wen, Y.J., Yi, T., et al., 2004. Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen. Eur. J. Immunol., 34(7):2012-2021.

[24] Tao, S.F., Chen, L., Zheng, Y.X., Xu, Y., Chen, J., Yu, H., 2006. Proliferation of endothelial cell on polytetrafluoroethylene vascular graft materials carried VEGF gene plasmid. J. Zhejiang Univ. Sci. B, 7(6):421-428.

[25] Thorpe, P.E., Burrows, F.J., 1995. Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res. Treat., 36(2):237-251.

[26] Vlodavsky, I., Friedmann, Y., 2001. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest., 108(3):341-347.

[27] Wickham, T.J., Haskard, D., Segal, D., Kovesdi, I., 1997. Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation. Cancer Immunol. Immunother., 45(3-4):149-151.

[28] Zachary, I., 2001. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am. J. Physiol. Cell Physiol., 280(6):C1375-C1386.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE